Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 Europe Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 Europe C.difficile Market by Country
3.2 Europe Crohns Disease Market by Country
3.3 Europe IBS Market by Country
3.4 Europe Diabetes Market by Country
3.5 Europe Others Market by Country
Chapter 4. Europe Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 Germany Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 UK Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 UK Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 France Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 France Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 Russia Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 Russia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.5 Spain Live Biotherapeutic Products And Microbiome CDMO Market
4.5.1 Spain Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.6 Italy Live Biotherapeutic Products And Microbiome CDMO Market
4.6.1 Italy Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.7 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market
4.7.1 Rest of Europe Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
Unique Offerings 